Amphivena is an American biotech firm with a Belgian, Peter Van Vlasselaer, at the helm. Amphivena is developing therapeutics in the promising field of “immuno-oncology”, which uses the body’s own immune system to attack malignant tumour In brief, Amphivena’s molecules act as an engager by binding to cancer cells on the one hand and T-cells (white blood cells that play an important role in clearing the body of cancer) on the other hand, bringing these together to enable our immune system to attack the cancer cells with maximum effect.